Compare Global X Defense Tech ETF (SHLD) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Defense Tech ETF vs Viatris Inc — how do they compare? Global X Defense Tech ETF trades at $70.16, while Viatris Inc trades at $16.24 (market cap $18.69B). The key difference: Viatris Inc pays a 2.95% dividend while Global X Defense Tech ETF pays none, and Viatris Inc is trading nearer its 52-week high, Global X Defense Tech ETF nearer its low. Which is the better fit depends on your goals.
| SHLD | VTRS | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $78.02 | $17.86 |
52-Week Low | $58.20 | $9.49 |
Market Cap | — | $18.69B |
Enterprise Value | — | $30.80B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SHLD, the Global X Defense Tech ETF, trades at $70.08, up 0.33% with a bullish technical signal from moving averages but overbought RSI readings. Recent news highlights institutional accumulation, including Focus Financial Network increasing its stake by 55.4% in Q2 2026 (Defense World, 2026-08-11). The ETF provides diversified exposure to global defense stocks amid rising military spending trends.
Outlook is supported by geopolitical tensions and defense budget growth, but risks include policy shifts and valuation concerns. Analysts note SHLD's lower fees and tech focus versus peers, with a dividend of $0.19 scheduled for July 2026. Key resistance is at $70, with support at $69.
Viatris (VTRS) trades at $16.33, up 0.31% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $0.69, exceeding expectations, and revenue growth of 5% year-over-year. However, negative net income margins and a high P/E ratio of 236.2 highlight profitability challenges. Recent developments include FDA approval for Gwyn Lo contraceptive patch and ongoing divestitures to sharpen focus.
Outlook remains mixed: operational improvements and dividend payments offer stability, but persistent net losses and high debt pose risks. Analyst consensus leans Hold (61.54%), reflecting cautious optimism amid execution uncertainties. Investment appeal hinges on successful margin recovery and debt management in a competitive generic drug market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global X Defense Tech ETF
SHLD tracks the Global X Defense Tech Index, targeting companies that lead the technological transformation of the defense sector. It focuses on pure-play innovators in cybersecurity, artificial intelligence, robotics, and advanced military systems, excluding traditional commercial aerospace to maintain a high level of thematic purity.
Read more on SHLD →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
